Abstract
Myasthenia gravis is a neurological disease that causes poor quality of life. Mestinon® is the drug of choice. However, using the original medication may lead to high costs particularly in developing countries. We did a pilot study in previously diagnosed, stable generalized myasthenia gravis patients by switching Mestinon® to pyrimine 60, a generic form. After we enrolled 13 patients, 6 patients responded, 4 patients did not respond, and 4 patients had severe dry mouth and throat from pyrimine 60. Clinical characters, SF-36 scores, and composite scores in those who responded, did not response, and had side effects were compared. No patients had serious side effects or myasthenic crisis. In conclusion, pyrimine 60 may be as effective as mestinon® with minor side effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
